Piper Sandler Reiterates Buy Rating on Illumina, Inc.
Piper Sandler maintains its buy rating on Illumina with a $200 price target, a 13.75% upside from the current price.
Key Points
- Piper Sandler reiterated its buy rating on Illumina, Inc. with a $200 price target on July 1, 2026.
- Piper Sandler's $200 price target implies 13.75% upside from Illumina, Inc.'s ($ILMN) current $175.83 share price.
- Illumina's stock traded at $175.83 on Wednesday, with a market cap of $26.6 billion and a P/E ratio of 31.9.
- Recent insider activity includes both purchases and sales, with Chief Legal Officer Scott Davies selling shares on June 25, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Piper Sandler reiterated its buy rating on Illumina, Inc. (NasdaqGS: ILMN) on July 1, 2026. The firm set a price target of $200 for the genetic sequencing company. Shares of Illumina traded at $175.83 on Wednesday.
Piper Sandler vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Illumina, Inc. Stock Down 18.4%
Shares of Illumina, Inc. traded near $175.83 on Wednesday. The company has a market capitalization of about $26.6 billion and a P/E ratio of 31.9. Illumina's stock has seen a 52-week low of $88.00 and a high of $182.84. The company's 50-day moving average is $149.97, while the 200-day moving average is $128.97. Illumina also has a beta of 1.49, indicating its stock is more volatile than the broader market.
$ILMN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Illumina reported revenue of approximately $4.39 billion, reflecting a growth of 4.8%. The company's net margin stands at 19.4%, with a return on equity of 33.8%. Illumina is expected to announce its next earnings on July 30, 2026.
Insider Buying and Selling at Illumina, Inc.
Recent insider activity at Illumina includes various transactions. On June 25, 2026, Chief Legal Officer Scott Davies sold 615 shares at an average price of $180 under a planned sale. On June 16, 2026, Daniel Skovronsky purchased 1,674 shares at $164.28. Other sales include Patricia Leckman, SVP and Chief People Officer, who sold shares on June 5 and June 2, 2026.
Analysts Set New Price Targets
On July 1, 2026, Piper Sandler maintained its buy rating on Illumina with a $200 price target. Guggenheim also maintained a buy rating with the same target on June 29, 2026. Bernstein reinstated a hold rating with a $185 target on June 26, 2026, while Barclays maintained a sell rating with a $145 target on June 24, 2026. The consensus among 19 analysts is a buy, with a mean price target of $151.68.
About Illumina, Inc.
Illumina, Inc. is a healthcare company based in San Diego, California, specializing in genetic and genomic analysis. It offers sequencing and array-based solutions for a variety of customers, including research centers, academic institutions, and pharmaceutical companies. The company provides instruments, consumables, and services for whole-genome sequencing and targeted resequencing. Founded in 1998, Illumina is led by CEO Jacob Thaysen and employs approximately 8,600 people.
Bottom Line
Piper Sandler's reiterated buy rating with a $200 target reflects confidence in Illumina's growth potential. With its innovative solutions in genomic analysis, Illumina remains a key player in the healthcare sector. Investors should note that these ratings are based on past performance and future potential, and may not reflect current market conditions.
Get Illumina, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ILMN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.